Stock Scorecard
Stock Summary for Denali Therapeutics Inc (DNLI) - $14.20 as of 3/28/2025 2:49:31 PM EST
Total Score
9 out of 30
Safety Score
33 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for DNLI
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for DNLI
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for DNLI
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for DNLI
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for DNLI (33 out of 100)
| Stock Price Rating (Max of 10) | 5 |
| Historical Stock Price Rating (Max of 10) | 8 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 4 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for DNLI
Financial Details for DNLI
Company Overview |
|
|---|---|
| Ticker | DNLI |
| Company Name | Denali Therapeutics Inc |
| Country | USA |
| Description | Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company is headquartered in South San Francisco, California. |
| Sector Name | LIFE SCIENCES |
| Industry Name | BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) |
| Most Recent Quarter | 12/31/2024 |
| Next Earnings Date | 5/5/2025 |
Stock Price History |
|
| Last Day Price | 14.20 |
| Price 4 Years Ago | 44.60 |
| Last Day Price Updated | 3/28/2025 2:49:31 PM EST |
| Last Day Volume | 654,366 |
| Average Daily Volume | 1,168,191 |
| 52-Week High | 33.33 |
| 52-Week Low | 13.67 |
| Last Price to 52 Week Low | 3.88% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 53.93 |
| Sector PE | 40.10 |
| 5-Year Average PE | 18.63 |
| Free Cash Flow Ratio | 2.47 |
| Industry Free Cash Flow Ratio | 18.14 |
| Sector Free Cash Flow Ratio | 47.05 |
| Current Ratio Most Recent Quarter | 9.98 |
| Total Cash Per Share | 5.76 |
| Book Value Per Share Most Recent Quarter | 8.53 |
| Price to Book Ratio | 1.68 |
| Industry Price to Book Ratio | 11.03 |
| Sector Price to Book Ratio | 21.92 |
| Price to Sales Ratio Twelve Trailing Months | 3,643.65 |
| Industry Price to Sales Ratio Twelve Trailing Months | 59.91 |
| Sector Price to Sales Ratio Twelve Trailing Months | 27.78 |
| Analyst Buy Ratings | 14 |
| Analyst Strong Buy Ratings | 4 |
Share Statistics |
|
| Total Shares Outstanding | 145,215,000 |
| Market Capitalization | 2,062,053,000 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 55.45% |
| Reported EPS 12 Trailing Months | -2.57 |
| Reported EPS Past Year | -2.67 |
| Reported EPS Prior Year | -1.08 |
| Net Income Twelve Trailing Months | -427,493,000 |
| Net Income Past Year | -145,224,000 |
| Net Income Prior Year | -325,991,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | 20.67% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 836,559,000 |
| Total Cash Past Year | 1,034,511,000 |
| Total Cash Prior Year | 1,336,215,000 |
| Net Cash Position Most Recent Quarter | 836,559,000 |
| Net Cash Position Past Year | 1,034,511,000 |
| Long Term Debt Past Year | 0 |
| Long Term Debt Prior Year | 0 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 1.00 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 1,030,954,000 |
| Total Stockholder Equity Prior Year | 1,042,430,000 |
| Total Stockholder Equity Most Recent Quarter | 1,318,495,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -375,691,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -2.59 |
| Free Cash Flow Past Year | -370,930,000 |
| Free Cash Flow Prior Year | -262,549,000 |
Options |
|
| Put/Call Ratio | 0.02 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | -1.43 |
| MACD Signal | -1.53 |
| 20-Day Bollinger Lower Band | 13.92 |
| 20-Day Bollinger Middle Band | 20.72 |
| 20-Day Bollinger Upper Band | 27.52 |
| Beta | 1.46 |
| RSI | 33.69 |
| 50-Day SMA | 22.42 |
| 150-Day SMA | 24.66 |
| 200-Day SMA | 30.09 |
System |
|
| Modified | 3/28/2025 10:41:04 PM EST |